STOCK TITAN

Nurix Therapeutics, Inc. - $NRIX STOCK NEWS

Welcome to our dedicated page for Nurix Therapeutics news (Ticker: $NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nurix Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nurix Therapeutics's position in the market.

Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., will present an overview of the company's achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
conferences
-
Rhea-AI Summary
Nurix Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: NRIX), presented positive clinical data from its BTK degraders, NX-5948 and NX-2127, at the 65th American Society of Hematology Annual Meeting and Exposition. The data supports the development of these drugs in patients with relapsed or refractory B-cell malignancies, including CLL, MCL, DLBCL, MZL, FL, PCNS, and WM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) to Host Webcast Reviewing Clinical Data from Phase 1 Trials of BTK Degrader Programs NX-5945 and NX-2127
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) to participate in Stifel Healthcare Conference and Piper Sandler Healthcare Conference in November, with webcasts available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.31%
Tags
conferences
-
Rhea-AI Summary
Nurix Therapeutics, Inc. will present clinical data for its two BTK degrader programs, NX-5948 and NX-2127, at the 65th American Society of Hematology Annual Meeting. They will also present a trials in progress poster for its NX-1607 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
-
Rhea-AI Summary
Nurix Therapeutics, Inc. has announced that the FDA has placed a partial clinical hold on the U.S. Phase 1 NX-2127-001 study for B-cell malignancies. Screening and enrollment of new participants have been paused, but currently enrolled patients can continue treatment. The hold is due to the company's intention to transition to an improved manufacturing process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
Rhea-AI Summary
Nurix Therapeutics reports Q3 financial results and announces strategic collaboration with Seagen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
-
Rhea-AI Summary
Nurix and Seagen to develop Degrader-Antibody Conjugates (DACs) for cancer treatment. Nurix to receive $60M upfront payment + potential $3.4B in milestone payments + future royalties. Nurix retains option for U.S. profit sharing and co-promotion on 2 products. Nurix expects funding until Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.32%
Tags
none
-
Rhea-AI Summary
Nurix Therapeutics (Nasdaq: NRIX) announces CEO's participation in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
Nurix Therapeutics, Inc.

Nasdaq:NRIX

NRIX Rankings

NRIX Stock Data

926.39M
37.68M
2.65%
97.95%
14.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About NRIX

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe